drugset / Trial / NCT02814500

DP-R212 Pharmacokinetic Study Phase I

NCT02814500

Phase 1 Unknown 36 enrolled Alvogen Korea
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212

Timeline

Start
2016-07
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified
Subject DP-R212 Unknown
Subject Rosuvastatin Small molecule

Indications

No indication recorded.